Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
NORCROSS, Ga., April 07, 2016 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., the Company’s president, chief executive officer and chief medical officer, will present at Needham & Company’s 15th Annual Healthcare Conference on Wednesday, April 13, 2016 at 3:00 p.m. Eastern time. The conference is being held at the Westin Grand Hotel in New York City on April 12-13, 2016.
A live webcast of the presentation may be accessed on the company’s website at www.galectintherapeutics.com. The webcast and presentation will be archived for 90 days following the event.
About Galectin Therapeutics
Galectin Therapeutics is developing promising therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.
Contacts:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
[email protected].
or
LHA
Kim Golodetz
(212) 838-3777
[email protected]
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.
